Early Cytokine Release in Response to Live *Borrelia burgdorferi* Sensu Lato Spirochetes Is Largely Complement Independent

Kerstin Sandholm, Anna J. Henningsson, Susanne Säve, Sven Bergström, Pia Forsberg, Nina Jonsson, Jan Ernerudh, Kristina N. Ekdahl

Introduction

Lyme borreliosis is an infectious disease that is predominantly found in the northern hemisphere and is caused by the spirochetes of *Borrelia burgdorferi* sensu lato (s.l.) [1]. The infection can affect the skin, joints, heart, and/or nervous system [2,3]. At least three genospecies in the *B. burgdorferi* s.l. group have been identified as human pathogens [4] and have been shown to be associated with different clinical manifestations: *B. burgdorferi* sensu stricto (s.s.) is mainly associated with arthritis, *B. garinii* with neuroborreliosis, and *B. afzelii* with skin manifestations [1,5,6].

To survive in different hosts and tissues, it is crucial for the *Borrelia* spirochetes to overcome the human host’s immune response. The innate immune system is the first line of defence that the spirochetes encounter when entering the body. These reactions are the key determinants of the magnitude and quality of the early immune response, and they subsequently initiate and form the adaptive immune response [7]. The complement system is part of innate immunity and consists of a complex network of plasma and membrane-associated proteins that are activated in a cascade-like manner. It can be activated through three different pathways: the classical, lectin, and alternative, all of which
converge in a central step, the activation of C3 to generate C3b, which serves as both a ligand for immune adhesion and a subunit of the alternative pathway convertase. Complement activation induced by microbes leads to important defense mechanisms such as phagocytosis of the target and the formation of the membrane attack complex (MAC).

_Borrelia_ species differ in their ability to survive in the presence of complement, and they are classified as serum-resistant or serum-sensitive, based on a quantification of the amount of MAC formed on the bacterial membrane in _in vitro_ [8]. _B. afzelii_ is classified as serum-resistant and _B. burgdorferi_ s.s. as moderately resistant, whereas _B. garinii_ is sensitive to complement-mediated killing [9–12]. Studies have shown that resistance to complement is correlated with an ability of the isolates to recruit fluid-phase immune regulators, factor H (FH) and factor H-like-protein-1 (FHL-1), to the bacterial surface. This process promotes the inactivation and degradation of the alternative pathway C3 convertase and C3b, which in turn hinder downstream activation, leading to decreased formation of MAC and a higher rate of convertase and C3b, which in turn hinder downstream activation, inactivation and degradation of the alternative pathway C3 convertase. Complement activation is a major factor in early inflammation and phagocytosis of the target and the formation of the membrane attack complex (MAC).

Early Immune Response to Live _Borrelia_ spirochetes

The complement regulators of the FH family bind to complement regulator-acquiring surface proteins (CRASPs) that are expressed on the surface of _B. burgdorferi_ s.l., thereby reducing the alternative pathway of complement activation [16,17]. Expression of the five known CRASPs has been identified on the serum-resistant _B. afzelii_; in contrast, _B. garinii_, which is serum-sensitive, expresses only one CRASP with weak or no binding to FHL-1 and FH [17,18], indicating that resistance to complement is correlated with the expression of CRASPs. In _B. garinii_, phagocytosis and microbial killing, complement activation is a major factor in early inflammation and an important contributor to the release of cytokines and chemokines such as the pro-inflammatory IL1-β, IL-6, TNF, and CCL20 (MIP-3γ). These mediators are important for the recruitment of other components of the innate immune response as well as signaling with the adaptive immune system [19]. It is therefore reasonable to hypothesize that the early innate immune response, including complement activation, phagocytic capacity, and cytokine/chemokine release, is of great importance for the response to _B. burgdorferi_ s.l.

The overall aim of this study was to characterize complement activation and its role in early immune activation in response to _Borrelia_ spirochetes. _In vitro_ models based on clinical isolates of _B. garinii_ and _B. afzelii_, sensitive and resistant to complement activation, respectively, were used to investigate the importance of complement activation in phagocytosis and in the generation of cytokines and chemokines.

Materials and Methods

Heparin treatment of equipment

All equipment that came in contact with blood and plasma (tubes and pipette tips) was furnished with a heparin surface according to the manufacturer’s recommendations (Corline AB, Uppsala, Sweden).

Preparation of blood and plasma

Blood from healthy volunteers without (n = 8) or with (n = 1) specific anti- _Borrelia_ antibodies was collected in 6-mL Vacutainer plastic tubes (BD Bioscience, Plymouth, UK) with the addition of the specific thrombin inhibitor hirudin (Refudalan, Pharmion Ltd, Cambridge, UK), at a final concentration of 50 µg/mL blood. This study, using blood from healthy blood donors given their written consent, was performed with consent of the Ethical Committee of the University Hospital of Linköping, Sweden (Dnr 2013/358). Plasma was collected by centrifugation at 3000 g for 20 min and stored at −80°C. For viability studies, aliquots of plasma were heat inactivated by incubation at 56°C for 30 min. For the phagocytosis experiments and cytokine release assays, blood was collected as described above and used within 30 min. Anti- _Borrelia_ antibodies were measured in serum using the commercially available enzyme-linked immunosorbent assay (ELISA) kits Enzygnost Lyme link VlsE/IGG and Enzygnost Borreliosis IgM (DADE Behring, Marburg, Germany) on a BEP 2000 Advance System (Siemens Healthcare, Erlangen, Germany), according to the instructions from the manufacturer.

Bacterial strains and growth conditions

The _Borrelia_ strains used in this study were isolated in Sven Bergström’s laboratory, Umeå University, Sweden: _B. garinii_ LU59 from human cerebrospinal fluid (CSF) and _B. afzelii_ K78 from a human skin biopsy. Bacteria were grown in Barbour-Stoenner-Kelly (BSK) II medium [30] supplemented with 7% rabbit serum (Sigma Aldrich, St. Louis, MO, USA) at 37°C until the density reached 10^6–10^9 cells/mL.

Susceptibility of _B. garinii_ LU59 and _B. afzelii_ K78 to complement

In initial experiments, the susceptibility of both _Borrelia_ strains to complement was investigated. Aliquots of _B. garinii_ LU59 and _B. afzelii_ K78 were incubated for 60 min at 37°C in serially diluted heat inactivated or native hirudin plasma, collected from a blood donor without _Borrelia_-specific antibodies. After incubation, the number of motile and non-motile spirochetes was counted in a phase contrast microscope [20,21].

Complement activation induced by _Borrelia_

Bacteria were washed with Dulbecco's PBS supplemented with 0.9 mM Ca<sup>2+</sup> (PBS<sup>Ca<sup>2+</sup>+</sup>) by centrifugation at 4500 g for 5 min, then resuspended and diluted in PBS<sup>Ca<sup>2+</sup>+</sup>. Aliquots of 50 µL _B. garinii_ LU59 and _B. afzelii_ K78 spirochetes (10^7/mL plasma) were incubated in 450 µL hirudin plasma (n = 8) without _Borrelia_-specific antibodies for 60 min at 37°C in 2-mL tubes. The reactions were stopped by the addition of ethylenediaminetetra-acetic acid (EDTA, 10 mM final concentration; Sigma Aldrich) and centrifuged at 4500 g for 5 min. All incubations were performed in duplicate. Hirudin plasma incubated without spirochetes was used as a control. Complement activation was monitored as the generation of activation product C3a and sC5b-9 complexes, measured in the plasma by ELISA as described previously [22,23]. Data are presented as the activation compared to a plasma control incubated in parallel, but without the presence of spirochetes.

Quantification of C3/C4 fragments, FH, and C4BP by ELISA

_B. garinii_ LU59 and _B. afzelii_ K78 (10^7/mL, plasma) were incubated in hirudin plasma (n = 3) or PBS<sup>Ca<sup>2+</sup>+</sup> at 37°C for 30 min and then centrifuged at 4500 g for 5 min. The pellets with spirochetes were washed three times with 500 µL PBS<sup>Ca<sup>2+</sup>+</sup> and then resuspended in PBS<sup>Ca<sup>2+</sup>+</sup> and transferred to new tubes. Biotinylated antibodies against human C3c (1.09 µg/mL), C4c (0.56 µg/mL), (Dako, Glostrup, Denmark), FH (1.13 µg/mL) and C4BP (1.44 µg/mL) (Binding Site, Birmingham, UK) were added,
pellet containing the spirochetes was washed four times with PBS and incubated with streptavidin-HRP (1:500; GE Healthcare, Uppsala, Sweden), washed four times, and stained with o-phenylenediamine (OPD; Sigma Aldrich). The absorbance was measured at 492 nm.

**Visualization of C3 fragments and FH by immunostaining and Western blot**

Spirochetes (10^7/mL plasma) were incubated for 30 min in hirudin plasma or PBSCa^2+ at 37°C. Complement activation was stopped by the addition of EDTA to a final concentration of 10 mM. Samples were centrifuged at 4500 g for 5 min, and the pellet containing the spirochetes was washed four times with PBSCa^2+ and analyzed for C3 fragments and FH by immunostaining and Western blot. For immunostaining, the spirochetes were incubated for 30 min with polyclonal anti-bodies against human C3c, which also detects intact C3, C3b, and iC3b (200 μg/mL; Dako), FH (250 μg/mL; Binding Site), and Borrelia (280 μg/mL; Acris, Herford, Germany). All antibodies were conjugated with Alexa Fluor Protein Labeling Kits (Life Technologies, Grand Island, NY, USA). Alexa Fluor 488 was used for anti-C3c and anti-FH and Alexa Fluor 555 for anti-Borrelia antibodies. Samples were washed, and fluorescence was examined with a Nikon Eclipse E600 Confocal Microscope and Nikon ConfoLocal Microscope EZ-C1 2.20 software (Nikon, Chiyoda, Tokyo, Japan).

Analysis of adsorbed proteins was also performed by SDS-polyacrylamide gel electrophoresis under reducing conditions. The proteins were either silver stained (Bio-Rad, Hercules, CA, USA) or transferred to a polyvinylidene fluoride (PVDF) Immune-Blot membrane (Bio-Rad). Detection was performed using biotinylated antibodies against human FH (0.57 μg/mL; Binding Site) and C3c (1.09 μg/mL; Dako), followed by streptavidin-HRP (1:500; GE Healthcare). Proteins were visualized with ECL Plus Western blot detection system (GE Healthcare). Human C3, C3b, iC3b and FH, purified as described earlier, served as controls [24]. The relative amount of Borrelia and total protein was visualized by SDS-PAGE followed by silver staining. A 20 kDa-band of bacterial orgin, most likely OspE [25] was used as loading control for SDS-PAGE experiments [26]. Six separate blots were performed using plasma from different donors. Quantification of the bound proteins was performed using public domain software (Java-based ImageJ software) from the NIH. The β-chain was chosen for quantification of the amount of bound C3-fragments because it is not subject to proteolytic cleavage resulting in transformation to C3b and iC3b.

**Labeling of spirochetes with FITC**

Spirochetes were labeled by a modification of the procedure described by Hazenbos et al. [27]. *B. garinii* LU59 and *B. afzelii* K78 were washed with 2 mL of 50 mM sodium carbonate with 100 mM sodium chloride, pH 7.4 (Sigma Aldrich), then centrifuged at 4500 g for 5 min. The pellets were suspended in 1 mL fluorescein isothiocyanate (0.5 mg/mL; FITC; Sigma Aldrich) in 50 mM sodium carbonate and 100 mM sodium chloride, pH 7.4, and incubated at RT for 20 min on a shaker. Washed three times with 4 mL PBSCa^2+, centrifuged at 4500 g for 5 min, and suspended in 2 mL PBSCa^2+. The spirochetes were visualized by fluorescence microscopy and their motility was unchanged by the labeling procedure [20,21].

**Phagocytosis of spirochetes**

Samples of 50 μL FITC-labeled *B. garinii* LU59 or *B. afzelii* K78 spirochetes (10^7/mL blood) were incubated in 450 μL hirudin blood without (n = 3) or with (n = 1) Borrelia-specific antibodies for 30 min at 37°C in 2 mL tubes. EDTA, which binds the Ca^2+ and Mg^2+ that are necessary for a functional complement system and therefore completely inhibits complement activation, was used at a final concentration of 10 mM as a negative control. Two additional inhibitors were used, 50 μM compstatin (Ac-ICV(1-Me-W)QDGWAHRCT-NH2), a synthetic peptide inhibiting the activation of C3 by the two C3 convertases [28]; and 5.5 μM C5a receptor antagonist (PMX53; C5aRa), which blocks the C5a-mediated up-regulation of granulocytes and monocytes. A scrambled peptide of C5aRa (5.5 μM) was used as a control. The peptides were a kind gift from Dr. John D. Lambris (the University of Pennsylvania, Philadelphia, PA, USA). Reactions were stopped by the addition of 10 mM EDTA (final concentration). Samples (100 μL) of hirudin blood from the incubations were transferred to new tubes, and 2 mL AKC lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 M EDTA; Sigma Aldrich) was added to remove and lyse the red blood cells. The reaction was allowed to continue for 5–10 min until the supernatants were clear red. After centrifugation at 400 g for 5 min, the supernatants were discarded. The pellets (leukocytes) were washed with 3 mL PBS supplemented with 1% (w/v) bovine serum albumin (BSA; Sigma Aldrich), and then 1.5 mL PBS with 1% paraformaldehyde (Apoteket, Gothenburg, Sweden) and 0.075% trypsin blue were added to quench extracellular fluorescence [29,30]. Granulocytes and monocytes were analyzed according to size (forward scatter) and granularity (side scatter) using flow cytometry (Cell lab Quanta SC, Beckman Coulter, Miami, FL, USA); 5,000 granulocytes were collected, resulting in the collection of ~500 monocytes. Data are presented as mean fluorescence intensity (MFI). Phagocytosis without complement inhibitors was set to 100%.

**Cytokine and chemokine release**

Hirudin blood without anti-*Borrelia* antibodies (n = 3, same individuals as for the phagocytosis experiments described above) was used. Washed spirochetes (10^7/mL) were incubated in 450 μL of hirudin blood at 37°C for 4 h, with or without the addition of complement inhibitors at a final concentration of 50 μM for compstatin and 100 μg/mL for the monoclonal antibody ecuizumab (Soliris, Alexion Pharmaceuticals, Cheshire, CT, USA), which binds to C5 and prevents its activation. Hirudin blood incubated without spirochetes was used as a control. All incubations were performed in duplicate. Further complement activation was stopped by the addition of 10 mM EDTA (final concentration) and centrifuged at 3000 g for 20 min, and the resulting plasma samples were frozen immediately at −80°C. In addition, plasma samples for determination of base-line level of each cytokine or chemokine for each donor were collected directly, without incubation. Complement activation was monitored as the generation of the activation products C3a and sC5b-9 complexes (not shown). Cytokine and chemokine concentrations were measured by Luminex xMAP technology (Milliplex Human Cytokine/Chemokine Kit, Merck Millipore, Billerica, MA, USA) according to the instructions provided by the manufacturer. The analyzed cytokines and chemokines were: IL-1β, IL-6, IL-10, IL-12(p70), IL-17A, IL-23, TNF, GM-CSF, CXCL10 (IP-10), CXCL1 (GRO-α), CXCL2 (MDC), CXCL8 (IL-8), CXCL20 (MIP3-α), and CCL2 (MCP-1). Values under the detection limit were given half the value of the lowest point of the standard curve. The inter-assay coefficients of variation (CV) were 3.5–16.4%, and
the intra-assay CVs were 3.9–10.5%, according to the manufacturer.

Statistics

All data were normalized against plasma without bacteria that was treated in the same way as the samples; data are presented as means ± SEM. Statistical analysis of data was performed using Prism version 6.0 for Macintosh software (GraphPad, San Diego, CA, USA). Differences between means were evaluated using paired t-tests and one-way ANOVA followed by Dunnetts post hoc test, and p-values<0.05 were considered to be significant.

Results

Susceptibility of *B. garinii* LU59 and *B. afzelii* K78 to complement

*B. garinii* LU59 was highly sensitive to complement with 22 and 40% motile spirochetes remaining after incubation in hirudin plasma diluted 1:3 respectively 1:9. No motile spirochetes were found after incubation with undiluted plasma, while the presence of neither heat-inactivated nor native plasma in higher dilutions affected the viability. Complement activation by *B. garinii* LU59 was most likely induced by the alternative pathway since it requires high concentration (>10%) of all participating components [31]. Incubation with hirudin plasma under these conditions did not affect the motility of *B. afzelii* K78.

Complement activation induced by spirochetes

Complement activation by spirochetes in hirudin plasma was monitored by the generation of C3a and C5b-9 complexes. When plasma without *Borrelia*-specific antibodies was used, higher levels of both activation products were found in plasma incubated with *B. garinii* LU59 when compared to plasma incubated with *B. afzelii* K78 (p<0.01) (Figure 1A). An identical experimental setup using plasma with anti-*Borrelia* IgG antibodies (n = 1) showed a higher activation of complement than when the antibodies were not present. In this setting, no significant difference was found between the two bacterial strains (data not shown).

Quantification of C3/C4 fragments, FH, and C4BP bound to spirochetes

In order to attempt to explain the differences in complement activation between the two strains of bacteria, we analyzed the regulatory proteins FH and C4BP, as well as fragments of C3 and C4 bound to the spirochetes. An ELISA-like assay was developed in which spirochetes were incubated in plasma to allow the binding of complement proteins. *B. garinii* LU59 was found to bind significantly more C3-fragments compared to *B. afzelii* K78 (p<0.05) while the opposite was true for binding of the regulatory protein FH (p<0.01) (Figure 1B). Similar differences, i.e., that the total amount of C3 bound to LU59 was more than double compared to K78 (p<0.0001), while the opposite binding was true for FH (p<0.01), were found by densitometric scanning of western blots (Figure 1C). In addition, both C4 (fragments) and the inhibitor C4BP were detected, albeit at low levels and with no significant difference between the two strains (data not shown).

In addition, immunostaining was used to ascertain that the detected C3 and FH indeed adhered to the spirochetes (data not shown). Silver staining of SDS-gels showed equal amount of bacteria in each sample and similar amounts of protein for both strains after incubation in plasma (Figure 1D). Western blots were performed to investigate the structure of the bound C3 (i.e. C3, C3b or iC3b), and whether FHL-1 and/or FH related proteins (FHR), bound in addition to FH (as well as for quantification). One representative example of six blots is shown (Figure 1E and F). These experiments were performed with an anti-C3c antibody that also detects degraded fragments of C3, and with an anti-FH antibody with an affinity for the FHL-1 and FHR proteins. Western blots showed that the C3 bound to both strains of spirochetes was quantitatively degraded to its inactive form iC3b, which is unable to form the alternative convertase but still functions as an opsonizing fragment. In the lanes containing opsonized *Borrelia*, the transition to iC3b is visualized by the total degradation of the z-chain and the appearance of the 40 kDa band (Figure 1E).

Phagocytosis of spirochetes

Phagocytosis of *B. afzelii* K78 by granulocytes was more efficient than that of *B. garinii* LU59 within a 5- to 30-min time period, (Figure 2A) with significant difference (p<0.05) at 30 min. To elucidate the importance of complement activation for efficient phagocytosis, we used inhibitors acting on different levels of the complement cascade (Figure 2B). The C5aRa showed an approximately 80% inhibition for both strains, with no synergy between the two inhibitors. The decrease in phagocytosis of each *Borrelia* strain by the two inhibitors, alone or in combination, were highly significant (p<0.0001). Similar results were obtained regarding phagocytosis by monocytes (data not shown). In the presence of *Borrelia*-specific antibodies, phagocytosis of *B. garinii* LU59 was inhibited by 70% in the presence of either inhibitor. *B. afzelii* K78 was 45% inhibited by compstatin and 60% by C5aRa (data not shown).

Cytokine and chemokine release

As a measure of the early inflammatory response to *Borrelia* infection, we analyzed the levels of secreted cytokines and chemokines after 4 h of incubation of hirudin blood with or without *Borrelia* spirochetes. After exposure to *Borrelia* spirochetes, we saw increases in the secreted levels of IL-1β (10,000-fold), IL-6 (400-fold), TNF (140-fold), CCL20 (40-fold), IL-10 (35-fold), CXCL8 (15-fold), GM-CSF (10-fold), CXCL10 (9-fold), IL-23 (7-fold), IL-12p70 (4-fold), CXCL1 (4-fold), and IL-17A (1.5-fold), although the levels did not differ significantly between *B. afzelii* K78 and *B. garinii* LU59 (Figure 3A). CCL22 and CXCL1 did not reach levels above the detection limit of the assay. The pro-inflammatory cytokines IL-1β, IL-6, TNF, CCL20, and CXCL8, together with the anti-inflammatory IL-10, increased the most, i.e., more than 10-fold in comparison with the control. Therefore, these cytokines and chemokines were used to further elucidate the importance of complement activation for their release (Figure 3B and C). Inhibition of complement at the levels of C3α and C5α generation showed no significant effect on cytokine or chemokine release, the only exception being CXCL8, which showed a significant 60% decrease for LU59 in the presence of compstatin (Figure 3C). The background levels of all cytokines (i.e. in plasma which was collected immediately, without incubation) were all below the detection limit in each blood donor.

Discussion

In the present study, we have investigated functional aspects of the early innate immune response to *B. afzelii* K78 and *B. garinii* LU59 by examining complement activation, phagocytosis, and cytokine and chemokine release.

One main finding regarding complement activation was the significant difference in found between the two strains of *Borrelia*. In accordance with previous findings [32], we found that the
complement-sensitive strain *B. garinii* LU59 induced a higher level of complement activation, as measured by the generation of C3a and sC5b-9 in plasma and detected by ELISA. Complement activation induced by the presence of *Borrelia*-specific antibodies resulted in a significant increase in generated sC5b-9, in agreement with other studies of the deposition of C5b-9 on the *Borrelia* spirochete incubated in hirudin plasma.

**Figure 1.** Complement activation and adherence of complement proteins to *Borrelia* spirochetes incubated in hirudin plasma. A) The ability of the *Borrelia* strains *B. afzelii* K78 and *B. garinii* LU59, resistant and sensitive to complement activation, respectively, to activate complement in hirudin plasma (n = 8) was assessed by analyzing the generation of C3a and sC5b-9 using ELISA. Data are normalized against plasma incubated without bacteria and are presented as means ± SEM. B) *Borrelia* were incubated with hirudin plasma (n = 6), and bound proteins were analyzed using an in-house-developed particle ELISA. Data are shown as absorbance values of bacteria incubated in plasma, normalized against bacteria incubated in PBSCa²⁺, and are presented as means ± SEM. C) Quantification of bound C3-fragments (using the β-chain that is not proteolytically cleaved) and FH. Results are presented normalized to either K78 or LU59 as mean of six Western blots. D) Silver stained SDS–PAGE of *B. afzelii* K78 and *B. garinii* LU59 non-opsonized (PBS) or opsonised (Pl). In addition, C3 and its fragments (E) and FH (F) bound to bacteria incubated with plasma (Pl) were visualized using Western blot with bacteria incubated in PBSCa²⁺ as controls, and purified C3, C3b and iC3b or FH as references. Insert: loading control, consisting of a 20kDa *Borrelia* protein that was detected on the membranes after detection with antibodies.

doi:10.1371/journal.pone.0108013.g001

**Figure 2.** Importance of complement activation for efficient phagocytosis. FITC-labeled *B. afzelii* K78 and *B. garinii* LU59 were incubated in hirudin blood to study phagocytosis by measuring the mean fluorescence intensity (MFI) for granulocytes. A) Phagocytosis of each bacterial strain was monitored for 30 min. Results are presented as mean ± SEM of two observations. B) The importance of complement activation in phagocytosis was analyzed by incubating *Borrelia* spirochetes in hirudin blood (n = 3) with the addition of complement inhibitors acting at different stages in the activation cascade. Compstatin selectively inhibits the proteolytic activation of C3 and a C5a receptor antagonist (C5aRa) that blocks the C5a-mediated up-regulation of granulocytes and monocytes. A scrambled peptide of C5aRa was used as a control. The mean fluorescence intensity (MFI) for each bacterial strain incubated in hirudin blood without complement inhibitors was set to 100%. EDTA: ethylenediaminetetraacetic acid. C5aRa: C5a receptor antagonist.

doi:10.1371/journal.pone.0108013.g002
complement regulators to the bacterial surface is an established mechanism used by pathogens to avoid complement attack [35–37]. Here we investigated the two main regulators of the alternative and classical pathway, FH and C4BP and both of which act as co-factors for factor I (FI)-mediated degradation of C3b and C4b, respectively [38–40]. Regulatory proteins bound to the membrane of B. garinii LU59 and B. afzelii K78 were quantified by an in-house-developed particle ELISA, as well as by western blotting (FH) confirming that B. afzelii K78 had recruited more FH (at least twice as much) than had the complement-sensitive B. garinii LU59, an observation also made by others [10,13,41]. Furthermore, we detected significantly higher amounts of deposited C3 on LU59 by both techniques, more than twice the amount found on K78, which is in agreement with the higher amount of C3a (and subsequently sC5b-9), generated by LU59. Interestingly, western blot analysis showed that the deposited C3 had been quantitatively degraded to iC3b on both strains despite the fourfold difference in C3/FH ratio, suggesting that FH may not be the limiting factor under the experimental conditions used here.

In addition, low amounts of C4BP were detected on both strains, with a non-significantly higher level on B. garinii LU59. Binding of C4BP to B. garinii in the literature is contradictory, studies in which no binding of C4BP was detected when a similar experimental setup has been reported [13,32] as well as studies in line with data presented here where binding of C4BP is observed [15].

Microbes are generally cleared from the body by phagocytosis. The Borrelia spirochetes used in this study were phagocytosed by both granulocytes and monocytes, a finding that has previously been demonstrated using other B. burgdorferi s.l [42–44]. For these studies we used FITC-labeling, which is a standard technique to study opsonization and phagocytosis of pathogens [45,46]. Intriguingly, the phagocytosis assay showed that B. afzelii K78 was more extensively phagocytosed than was B. garinii LU59 at all time points, a result that has not been reported previously. It is most unlikely that this difference in phagocytosis is a consequence of differences in viability since live and dead bacteria are phagocytosed by granulocytes at similar rate [47].

When we examined the importance of complement activation in phagocytosis by using several complement inhibitors interfering with the activation of complement at different stages in the activation cascade, we found that phagocytosis was obliterated in the presence of the complement inhibitor EDTA, a chelator that binds Ca2+ and Mg2+. These ions are necessary for a functional complement system but also for a number of other biochemical reactions so the addition of EDTA could possibly have affected other mechanisms involved in phagocytosis, and not uniquely the complement system. Therefore, we also tested the effects of complement inhibitors acting at the levels of C3 and C5, respectively. Both inhibitors produced a 50–80% reduction in phagocytosis, without any obvious synergistic effects. Although it can not be totally excluded that the FITC-labeling procedure per se may affect activation and binding of complement proteins to the pathogen surface, the marked effect on phagocytosis seen using compstatin and C5aRa makes this option less likely. The effect of complement inhibition on phagocytosis was less prominent in the presence of Borrelia-specific antibodies. Consequently, complement activation is most important but not completely essential for phagocytosis. This observation is supported by other in vitro studies of human neutrophils as well as by in vivo studies using C3 knockout mice [42,48].

Regarding the analysis of early cytokine and chemokine release in human blood in response to live spirochetes, we found a rapid increase in the panel of cytokines and chemokines analyzed in this report showed no difference without the addition of bacteria. (A) The x-fold increase in the panel of cytokine/chemokine production was then measured using a Luminex-based assay. Results are normalized against the values for plasma...

Figure 3. Cytokine and chemokine levels in plasma as a response to incubation with Borrelia spirochetes. Spirochetes were incubated in whole blood (n = 3) in duplicate for 4 h, and the cytokine/chemokine production was then measured using a Luminex-based assay. Results are normalized against the values for plasma without the addition of bacteria. (A) The x-fold increase in the panel of cytokines and chemokines analyzed in this report showed no difference between the complement-resistant B. afzelii K78 and -sensitive B. garinii LU59. (B and C) The importance of complement activation was further investigated using two complement inhibitors: compstatin, which selectively inhibits the proteolytic activation of C3, and eculizumab, an anti-C5 antibody blocking the cleavage of C5 and therefore further complement activation and C5a mediated signaling. Data are presented as means ± SEM.

doi:10.1371/journal.pone.0108013.g003
and pronounced pro-inflammatory response, with high levels of major inflammatory mediators such as IL-1β, IL-6, TNF, and CXCL10, an observation that is in line with previous reports [19,49,50]. Interestingly, the T helper (Th) 17-recruiting chemokine CCL20 was also highly induced, as well as the Th17-inducing cytokine IL-25. In addition, pro-inflammatory IL-6 rises in Th17 induction, and CXCL8 is in part associated with Th17. These findings are in line with recent observations of Th17-like immunity in neuroborreliosis [51–53] and Lyme arthritis [54]. Furthermore, Th1-inducing IL-12p70, as well as Th1-recruiting CXCL10, were among the highly induced cytokines, whereas the Th2-recruiting CCL22 was not induced at all. Thus, the pattern we observed could reflect the ensuing adaptive response that is characterized by Th1 predominance over Th2 reactivity [51,53,55–57]. Notably, we found that already after 4 h of incubation with Borrelia spirochetes, there were significantly elevated levels of IL-10. IL-10 is considered a key negative regulator of pro-inflammatory cytokine release and function [58]. It has been shown that B. burgdorferi s.l. induces the secretion of IL-10 in mononuclear cells, and the clearance of B. burgdorferi s.l. in IL-10-deficient mice is 10-fold higher than that in wild-type mice [59]. These studies, together with our findings suggest, that B. burgdorferi s.l. itself may induce IL-10 to inhibit the host defense.

Activation of pattern recognition receptors (PRR), such as toll-like receptors (TLR), by conserved lipoproteins on the spirochetal membrane enhances phagocytosis and antigen presentation, as well as triggering the production and release of inflammatory cytokines [60,61]. TLR activation induced by Borrelia spirochetes has been shown to induce the activation of the transcription factor NFκB, which is involved in the production of pro-inflammatory cytokines [62,63]. In the present study, we showed a 10- to 10,000-fold increase in the release of pro-inflammatory cytokines when compared to background levels. IL-1β increased the most (i.e., 10 times more than IL-6). IL-1β has previously been connected with the activation of PRR as a response to Borrelia spirochetes [64]. It has recently been suggested that autophagy is responsible for an increased production of IL-1ß and IL-6 in peripheral mononuclear blood cells as a response to B. burgdorferi s.l. [65]. Furthermore, differences in cytokine response has been described following phagocytosis depending on the viability of E.coli: both dead and live bacteria are reported to induce, e.g. IL-6 to similar extent and Monocytes participate in the phagocytosis of Borrelia spirochetes and that complement activation is extremely important, but not crucial, for spirochetal phagocytosis; 3) that the early cytokine/chemokine response to Borrelia spirochetes was dominated by pro-inflammatory mediators and also by inducers and triggers of Th1- and Th17-like immunity; 4) that the assessed cytokine/chemokine response was not affected by the complement system in this in vitro model. Since only minor differences were found in response to the two strains, a valid conclusion from this work could be that there is enough redundancy in complement sufficient subjects to eradicate Borrelia infections.

Acknowledgments

The authors would like to thank MSc Petra Cassel, Division of Clinical Immunology, Department of Clinical and Experimental Medicine, Linköping University, for help with the Luminex assay; Ms Bodil Bagert for help with the initial motility determinations; Professor John Lambris, University of Pennsylvania, Philadelphia, PA, USA, for providing complement-resistant strain B. afzelii K78 and recruiting C18 in part could explain the neurotropism of the sensitive strain; 2) that both granulocytes and macrophages participate in the phagocytosis of Borrelia spirochetes and that complement activation is extremely important, but not crucial, for spirochetal phagocytosis; 3) that the early cytokine/chemokine response to Borrelia spirochetes was dominated by pro-inflammatory mediators and also by inducers and recruiters of Th1- and Th17-like immunity; 4) that the assessed cytokine/chemokine response was not affected by the complement system in this in vitro model. Since only minor differences were found in response to the two strains, a valid conclusion from this work could be that there is enough redundancy in complement sufficient subjects to eradicate Borrelia infections.

Author Contributions

Conceived and designed the experiments: KS AJH JE KNE. Performed the experiments: KS AJH SS NJ. Analyzed the data: KS AJH SS NJ JE KNE. Contributed reagents/materials/analysis tools: SB PF JE KNE. Wrote the paper: KS AJH SS NJ JE KNE.

References

1. Stanek G, Wormser GP, Gray J, Stire F (2012) Lyme borreliosis. Lancet 379:461–473.

2. Berglund J, Eitrem R, Ornstein K, Lindberg A, Ringer A, et al. (1995) An epidemiologic study of Lyme disease in southern Sweden. N Engl J Med 333:1319–1327.
3. Cinimmo MA (1998) Relative frequency of Lyme borreliosis and of its clinical manifestations in Europe. European Community Concerted Action on Risk Assessment in Lyme Borreliosis. Infection 26:298–300.

4. Baramont G, Prost D, Saint Girons I, Boehrin P, Piffaretci JC, et al. (1992) Determination of Borrelia burgdorferi sensu stricto. Borrelia garinii sp. nov., and group VN4614 associated with Lyme borreliosis. Int J Syst Bacteriol 42:378–383.

5. Bacon RM, Kugeler KJ, Mead PS (2008) Surveillance for Lyme disease–United States, 1992-2006. MMWR Surveill Summ 57:1–9.

6. van Dam AP, Kugeler KJ, Mead PS (2008) Surveillance for Lyme disease–United States, 1992-2006. MMWR Surveill Summ 57:1–9.

7. Salazar JC, Pope CD, Sellati TJ, Feder HM Jr, Kieley TG, et al. (2003) Co-aggregation of Borrelia burgdorferi and the adhesion molecule CD147 in skin and peripheral blood of patients with erythema migrans. J Immunol 171:2660–2670.

8. Breitner-Ruddock S, Wurzner R, Schulze J, Brade V (1997) Heterogeneity in the complement-dependent bacteriolysis within the species of Borrelia burgdorferi. Med Microbiol Immunol 16:235–260.

9. Mollnes TE, Lea T, Froland SS, Harboe M (1985) Quantification of the surface protein E to the C terminus of factor H. J Immunol 172:6195–6201.

10. Shamaei-Tousi A, Burns MJ, Benach JL, Furie MB, Gergel EI, et al. (2000) The development of an effective membrane attack complex. J Immunol 165:1228–1236.

11. Bykowski T, Woodman ME, Cooley AE, Brissette CA, Wallich R, et al. (2008) Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci U S A 105:1657–1661.

12. Ko YP, Kuipers A, Freitag CM, Jongerius I, Medina E, et al. (2013) Borrelia burgdorferi complement regulator-acquiring surface proteins (BbCRASPs): Expression patterns during the mammal-tick infection cycle. J Biol Chem 288:13047–13056.

13. Bacon RM, Kugeler KJ, Mead PS (2008) Surveillance for Lyme disease–United States, 1992-2006. MMWR Surveill Summ 57:1–9.

14. Henningsson AJ, Tjernberg I, Malmvall BE, Forsberg P, Ernerudh J (2011) Co-aggregation of Borrelia burgdorferi sensu lato–the key role of host complement. Immunobiology 216:581–590.

15. Pietikainen J, Meri T, Cutler SJ, Blom AM, Meri S (2010) Binding of the complement inhibitor C8b-binding protein to Lyme disease Borreliae. Mol Immunol 47:1299–1303.

16. Alitalo A, Meri T, Blom AM, Meri S, Jokiranta TS, Heikila T, et al. (2001) Complement dependent multipoint binding of the Borrelia burgdorferi virulence factor outer surface protein E to the C terminus of factor H. J Biol Chem 276:827–8415.

17. Jozsi M, Zipfel PF (2008) Factor H family proteins and human diseases. Trends Immunol 9:729–740.

18. Bykowski T, Woodman ME, Cooley AE, Brissette CA, Wallich R, et al. (2008) Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci U S A 105:1657–1661.

19. Jaenecic R, Lannef L, Sjoholm AG, Pozzi G, Bjorkl I (2000) A novel surface protein of Streptococcus pneumoniae that interferes with complement function. J Biol Chem 275:37257–37263.

20. Ekerfelt C, Ernerudh J, Bunikis J, Vrethem M, Aagesen J, et al. (1997) Early immune response to Live Babesia microti in a population in Skane with a high incidence of Babesia infection. J Infect Dis 175:1415–1422.

21. Kuhn S, Skerka C, Zipfel PF (1995) Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1. J Immunol 155:5663–5670.

22. Suhonen J, Komi J, Soukka J, Lassila O, Viljanen MK (2003) Interaction of an effective membrane attack complex. J Immunol 171:2660–2670.

23. Horstmann RD, Sievertsen HJ, Knobloch J, Fuchetti VA (1983) Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci U S A 105:1657–1661.

24. Mollnes TE, Lea T, Froland SS, Harboe M (1985) Quantification of the surface protein E to the C terminus of factor H. J Immunol 172:6195–6201.

25. Horstmann RD, Sievertsen HJ, Knobloch J, Fuchetti VA (1983) Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci U S A 105:1657–1661.

26. Henningsson AJ, Tjernberg I, Malmvall BE, Forsberg P, Ernerudh J (2011) Co-aggregation of Borrelia burgdorferi sensu lato–the key role of host complement. Immunobiology 216:581–590.

27. Ko YP, Kuipers A, Freitag CM, Jongerius I, Medina E, et al. (2013) Borrelia burgdorferi complement regulator-acquiring surface proteins (BbCRASPs): Expression patterns during the mammal-tick infection cycle. J Biol Chem 288:13047–13056.
IL-4 secretion in response to outer surface proteins of Lyme disease Borrelia spirochetes. J Neuroimmunol 79:155–162.

56. Widhe M, Jarefors S, Ekerfelt C, Vrethem M, Bergstrom S, et al. (2004) Borrelia-specific interferon-gamma and interleukin-4 secretion in cerebrospinal fluid and blood during Lyme borreliosis in humans: association with clinical outcome. J Infect Dis 189:1881–1891.

57. Sjowall J, Carlsson A, Vaarala O, Bergstrom S, Ernerudh J, et al. (2005) Innate immune responses in Lyme borreliosis: enhanced tumour necrosis factor-alpha and interleukin-12 in asymptomatic individuals in response to live spirochetes. Clin Exp Immunol 141:89–98.

58. Giambartolomei GH, Dennis VA, Philipp MT (1998) Borrelia burgdorferi stimulates the production of interleukin-10 in peripheral blood mononuclear cells from uninfected humans and rhesus monkeys. Infect Immun 66:2691–2697.

59. Lazarus JJ, Meadows MJ, Lannert RE, Wooten RM (2006) IL-10 deficiency promotes increased Borrelia burgdorferi clearance predominantly through enhanced innate immune responses. J Immunol 177:7076–7085.

60. Steere AC, Angelis SM (2006) Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 54:3079–3086.

61. Blander JM, Medzhitov R (2006) Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440:808–812.

62. Hirschfeld M, Kirschning CJ, Schwandner R, Wesche H, Weiss JH, et al. (1999) Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J Immunol 163:2382–2386.

63. Alexopoulou L, Thomas V, Schmare M, Lober Y, Anguita J, et al. (2002) Hypersensitiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 8:878–884.

64. Petzke MM, Brooks A, Krupna MA, Morhac D, Schwartz I (2009) Recognition of Borrelia burgdorferi, the Lyme disease spirochete, by TLR7 and TLR9 induces a type I IFN response by human immune cells. J Immunol 183:5279–5292.

65. Buffen K, Oosting M, Mennens S, Anand PK, Plantinga TS, et al. (2013) Autophagy modulates Borrelia burgdorferi-induced production of interleukin-1beta (IL-1beta). J Biol Chem 288:8658–8666.

66. Underhill DM, Goodridge HS (2012) Information processing during phagocytosis. Nat Rev Immunol 12:492–502.

67. Cervantes JL, Dunham-Ems SM, La Vake CJ, Petzke MM, Sahay R, et al. (2011) Phagosomal signaling by Borrelia burgdorferi in human monocytes involves Toll-like receptor (TLR) 2 and TLR8 cooperativity and TLR8-mediated induction of IFN-beta. Proc Natl Acad Sci U S A 108:3603–3608.

68. Wilke B, Buech U, Eiffert H, Fingerle V, Pfeifer HW, et al. (1996) Diversity of OspA and OspC among cerebrospinal fluid isolates of Borrelia burgdorferi sensu lato from patients with neuroborreliosis in Germany. Med Microbiol Immunol 184:195–201.

69. van Burgel ND, Kraiczy P, Schrijver Tj, Zipfel PF, van Dam AP (2010) Identification and functional characterisation of Complement Regulator Acquiring Surface Protein-1 of serum resistant Borrelia garinii OspA serotype 4. BMC Microbiol 10:83.

70. Henningsson AJ, Ernerudh J, Sandholm K, Carlson SA, Granlund H, et al. (2007) Complement activation in Lyme neuroborreliosis—increased levels of C1q and C3a in cerebrospinal fluid indicate complement activation in the CNS. J Neuroimmunol 183:200–207.